Rethinking the INN system for therapeutic antibodies

mAbs

Volumn 9, Issue 1, 2017, Pages 5-11

  Pottier, Jérémy ^a,b   Chastang, Romane ^a,b   Dumet, Christophe ^a,b   Watier, Hervé ^a,b,c  

^a UNIVERSITÉ DE TOURS   (France)

^b CNRS   (France)

^c UNIVERSITY HOSPITAL OF TOURS   (France)

Author keywords

Allotypes; bispecific; Fc portion; IgG; INN; International Nonproprietary Name; monoclonal antibody; pharmacokinetics; recombinant; variants

Indexed keywords

ANTIBODY; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; RECOMBINANT ANTIBODY;

ALLOTYPE; ANTIGEN BINDING; HEALTH CARE PERSONNEL; HUMAN; INNER EAR; ANIMAL; NOMENCLATURE;

ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; TERMINOLOGY AS TOPIC;

EID: 85001968823     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2016.1255520     Document Type: Note

References (33)

1. Jones TD, Carter PJ, Plückthun A, Vásquez M, Holgate RGE, Hötzel I, Popplewell AG, Parren PWHI, Enzelberger M, Rademaker HJ, et al. The INNs and outs of antibody nonproprietary names. MAbs 2016; 8:1-9; PMID:26716992; http://dx.doi.org/10.1080/19420862.2015.1114320
2. World Health Organization. General policies for monoclonal antibodies. 2009; http://www.who.int/medicines/services/inn/Generalpoliciesformonoclonalantibodies2009.pdf
3. Watier H, Reichert J. Evolution of antibody therapeutics (Chapter 2). In:Jallal B, Vaughan T, Osbur J, eds Protein Therapeutics. Wiley, 2016 in press
4. World Health Organization. Expert Commitee of the Unification of Pharmacopoeias. Report on the Sixth Session. 1950; http://apps.who.int/iris/bitstream/10665/38948/1/WHO_TRS_29.pdf
5. Clark M. Antibody humanization:a case of the “Emperor”s new clothes’? Immunol Today 2000; 21:397–402; PMID:10916143; http://dx.doi.org/10.1016/S0167-5699(00)01680-7
6. Van Schie KA, Hart MH, de Groot ER, Kruithof S, Aarden LA, Wolbink GJ, Rispens T. The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region. Ann Rheum Dis 2015; 74:311–4; PMID:25342759; http://dx.doi.org/10.1136/ annrheumdis-2014-206237
7. Ratanji KD, Derrick JP, Dearman RJ, Kimber I. Immunogenicity of therapeutic proteins:influence of aggregation. J Immunotoxicol 2013; 11:99-109; PMID:23919460; http://dx.doi.org/10.3109/1547691X.2013.821564
8. Krishna M, Nadler SG. Immunogenicity to Biotherapeutics - The role of anti-drug immune complexes. Front Immunol 2016; 7:21; PMID:26870037; http://dx.doi.org/10.3389/fimmu.2016.00021
9. Chaigne B, Watier H. Monoclonal antibodies in excess:A simple way to avoid immunogenicity in patients? J Allergy Clin Immunol 2015; 136:814-6; PMID:25930194; http://dx.doi.org/10.1016/j.jaci.2015.03.013
10. Ober RJ, Radu CG, Ghetie V, Ward ES. Differences in promiscuity for antibody-FcRn interactions across species:implications for therapeutic antibodies. Int Immunol 2001; 13:1551-9; PMID:11717196; http://dx.doi.org/10.1093/intimm/13.12.1551
11. Magdelaine-Beuzelin C, Kaas Q, Wehbi V, Ohresser M, Jefferis R, Lefranc M-P, Watier H. Structure-function relationships of the variable domains of monoclonal antibodies approved for cancer treatment. Crit Rev Oncol Hematol 2007; 64:210-25; PMID:17624800; http://dx.doi.org/10.1016/j.critrevonc.2007.04.011
12. World Health Organization. WHO Drug Information 2009; 23:195-9. http://www.who.int/medicines/publications/druginformation/issues/DrugInfo09vol23-2.pdf
13. Sally Pepper, Malan S, Mignot G, Mattavelli RB. WHO Programme on International Nonproprietary Names (INN). Work Doc 15381 2015:29-34
14. World Health Organization. 62nd Consultation on International Nonproprietary Names for Pharmaceutical Substances. 2016; http://www.who.int/medicines/services/inn/62nd_Executive_Summary.pdf?ua=1
15. World Health Organization. International nonproprietary names (INN) for biological and biotechnological substances (a review). 2016; http://www.who.int/medicines/services/inn/BioReview2016.pdf
16. World Health Organization. 56th Consultation on International Nonproprietary Names for Pharmaceutical Substances. 2013; http://www.who.int/medicines/services/inn/56th_Executive_Summary.pdf
17. Thulliez M, Angoulvant D, Le Lez ML, Jonville-Bera A-P, Pisella P-J, Gueyffier F, Bejan-Angoulvant T. Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies:systematic review and meta-analysis. JAMA Ophthalmol 2014; 132:1317-26; PMID:25058694; http://dx.doi.org/10.1001/jamaophthalmol.2014.2333
18. Pèlegrin A, Daguet A, Watier H. MAbImprove:a French “Laboratoire d'excellence” (LabEx) dedicated to therapeutic antibodies. MAbs 2014; 6:803-4; http://dx.doi.org/10.4161/mabs.29262
19. Pandey JP, Namboodiri AM. Genetic variants of IgG1 antibodies and FcγRIIIa receptors influence the magnitude of antibody-dependent cell-mediated cytotoxicity against prostate cancer cells. Oncoimmunology 2014; 3:e27317; PMID:24701371; http://dx.doi.org/10.4161/onci.27317
20. Vidarsson G, Dekkers G, Rispens T. IgG Subclasses and Allotypes:From structure to effector functions. Front Immunol 2014; 5:1-17; http://dx.doi.org/10.3389/fimmu.2014.00520
21. Ternant D, Arnoult C, Pugnière M, Dhommée C, Drocourt D, Perouzel E, Passot C, Baroukh N, Mulleman D, Tiraby G, et al. IgG1 Allotypes Influence the Pharmacokinetics of Therapeutic Monoclonal Antibodies through FcRn Binding. J Immunol 2016; 196:607-13; PMID:26685205; http://dx.doi.org/10.4049/jimmunol.1501780
22. Stapleton NM, Andersen JT, Stemerding AM, Bjarnarson SP, Verheul RC, Gerritsen J, Zhao Y, Kleijer M, Sandlie I, de Haas M, et al. Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential. Nat Commun 2011; 2:599; PMID:22186895; http://dx.doi.org/10.1038/ncomms1608
23. Jefferis R, Lefranc M. Human immunoglobulin allotypes:possible implications for immunogenicity. MAbs 2009; 1:332-8; PMID:20073133; http://dx.doi.org/10.4161/mabs.1.4.9122
24. Winter GP, Duncan AR, Burton DR. Altered antibodies. 1987
25. Pottier J, Watier H, Gouilleux-Gruart V. Modifications in the IgG4 Fc portion of therapeutics in patents:opportunities for a twisting IgG subclass. Submitted 2016
26. White AL, Chan HTC, French RR, Willoughby J, Mockridge CI, Roghanian A, Penfold CA, Booth SG, Dodhy A, Polak ME, et al. conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies. Cancer Cell 2015; 27:138-48; PMID:25500122; http://dx.doi.org/10.1016/j.ccell.2014.11.001
27. Dillon TM, Ricci MS, Vezina C, Flynn GC, Liu YD, Rehder DS, Plant M, Henkle B, Li Y, Deechongkit S, et al. Structural and functional characterization of disulfide isoforms of the human IgG2 subclass. J Biol Chem 2008; 283:16206-15; PMID:18339626; http://dx.doi.org/10.1074/jbc.M709988200
28. Monnet C, Jorieux S, Urbain R, Fournier N, Bouayadi K, De Romeuf C, Behrens CK, Fontayne A, Mondon P. Selection of IgG variants with increased FcRn binding using random and directed mutagenesis:impact on effector functions. Front Immunol 2015; 6:1-14; PMID:25657648; http://dx.doi.org/10.3389/fimmu.2015.00039
29. Snowden A, Hayden I, Dixon J, Gregory G. Prevention and management of obinutuzumab-associated toxicities:Australian experience. Int J Nurs Pract 2015; 21 Suppl 3:15-27; PMID:26681665; http://dx.doi.org/10.1111/ijn.12412
30. Tse BC, Navid F, Billups CA, O'Donnell T, Hoehn ME. Ocular abnormalities in patients treated with a novel anti-GD2 monoclonal antibody, hu14.18K322A. J AAPOS 2015; 19:112-5; PMID:25818285; http://dx.doi.org/10.1016/j.jaapos.2014.11.005
31. Edelman GM, Cunningham BA, Gall WE, Gottlieb PD, Rutishauser U, Waxdal MJ. The covalent structure of an entire gamma G immunoglobulin molecule. Proc Natl Acad Sci U S A 1969; 63:78-85; PMID:5257969; http://dx.doi.org/10.1073/pnas.63.1.78
32. World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN):Recommended International Nonproprietary Names List 75. WHO Drug Inf 2016; 75:19; http://www.who.int/medicines/publications/druginformation/innlists/RL75.pdf?ua=1
33. Inbar D, Hochman J, Givol D. Localization of antibody-combining sites within the variable portions of heavy and light chains. Proc Natl Acad Sci U S A 1972; 69:2659-62; PMID:4560694; http://dx.doi.org/10.1073/pnas.69.9.2659